MY188046A - Antiviral activity of baicalein against japanese encephalitis virus - Google Patents

Antiviral activity of baicalein against japanese encephalitis virus

Info

Publication number
MY188046A
MY188046A MYPI2013000889A MYPI2013000889A MY188046A MY 188046 A MY188046 A MY 188046A MY PI2013000889 A MYPI2013000889 A MY PI2013000889A MY PI2013000889 A MYPI2013000889 A MY PI2013000889A MY 188046 A MY188046 A MY 188046A
Authority
MY
Malaysia
Prior art keywords
baicalein
jev
japanese encephalitis
antiviral activity
encephalitis virus
Prior art date
Application number
MYPI2013000889A
Inventor
Dr Sazaly Abu Bakar Prof
Prof Dr Keivan Zandi Associate
Iskandar Jefree Johari Mohd
Original Assignee
Univ Malaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Malaya filed Critical Univ Malaya
Priority to MYPI2013000889A priority Critical patent/MY188046A/en
Priority to PCT/MY2014/000031 priority patent/WO2014142644A1/en
Publication of MY188046A publication Critical patent/MY188046A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides an antiviral medicament for treating Japanese Encephalitis Virus (JEV) infection comprises a natural flavonoid compound namely baicalein. In the present invention, antiviral activity of baicalein was evaluated against JEV replication in African green monkey kidney cell line (Vero). Anti-JEV activities of baicalein were examined at different stages of JEV replication cycle. The effects of baicalein on virus replication were determined from Foci Forming Unit Reduction Assay (FFURA) and quantitative RT-PCR.
MYPI2013000889A 2013-03-15 2013-03-15 Antiviral activity of baicalein against japanese encephalitis virus MY188046A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI2013000889A MY188046A (en) 2013-03-15 2013-03-15 Antiviral activity of baicalein against japanese encephalitis virus
PCT/MY2014/000031 WO2014142644A1 (en) 2013-03-15 2014-03-13 Antiviral activity of baicalein against japanese encephalitis virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2013000889A MY188046A (en) 2013-03-15 2013-03-15 Antiviral activity of baicalein against japanese encephalitis virus

Publications (1)

Publication Number Publication Date
MY188046A true MY188046A (en) 2021-11-12

Family

ID=51537156

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013000889A MY188046A (en) 2013-03-15 2013-03-15 Antiviral activity of baicalein against japanese encephalitis virus

Country Status (2)

Country Link
MY (1) MY188046A (en)
WO (1) WO2014142644A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072826A (en) * 1992-03-12 1995-01-06 Sanwa Kagaku Kenkyusho Co Ltd Flavone derivative
MX2012012354A (en) * 2010-04-23 2013-03-07 Kineta Inc Anti-viral compounds.
MY151083A (en) * 2012-03-30 2014-04-04 Univ Malaya Antiviral composition against flavivirus

Also Published As

Publication number Publication date
WO2014142644A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CL2016000805A1 (en) Substituted nucleosides, nucleotides and analogs thereof.
MX2020005165A (en) Mirna biogenesis in exosomes for diagnosis and therapy.
PH12017501958B1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
CL2016000952A1 (en) Carboxamide derivatives and their use as medicines for the treatment of hepatitis b
MX2016004492A (en) Inhibitors of human immunodeficiency virus replication.
PH12015500073A1 (en) Macrocyclic purines for the treatment of viral infections
MX2015013809A (en) Macrocyclic deaza-purinones for the treatment of viral infections.
MY174018A (en) Heterocyclic derivates
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
NZ746139A (en) Methods for treating conditions associated with masp-2 dependent complement activation
DE112012006327A5 (en) Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
NZ745349A (en) Urea compound, preparation method therefor and medical use thereof
MX2017005350A (en) Therapy for inhibition of single-stranded rna virus replication.
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
CL2018001804A1 (en) Use of carrimicin in resistant mycobacterium tuberculosis infection
CO2018000171A2 (en) Methods of purification and / or viral inactivity
BR112017014416A2 (en) mangiferin-6-o-berberine salt and method of preparation and use thereof
MX2018014377A (en) Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors.
PH12020550673A1 (en) Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv)
MX356102B (en) Compounds and methods for treating leukemia.
MY188046A (en) Antiviral activity of baicalein against japanese encephalitis virus
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors